Otros idiomas Camurus AB

Acciones

CAMX

SE0007692850

Mercado cerrado - Nasdaq Stockholm Otros sitios de cotización 17:29:57 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
490 ^SEK	+2,81 %		+1,03 %	-8,92 %

02/04	Camurus AB (Publ) anuncia la dimisión de sus miembros del Consejo de Administración	CI
05/03	La FDA estadounidense acepta la solicitud de nuevo fármaco de Camurus para el tratamiento de la acromegalia	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Certain Shares of Camurus AB are subject to a Lock-Up Agreement Ending on 17-APR-2024.	17/04
Notice of annual general meeting 2024 in Camurus (publ)	02/04
Camurus AB Announces Board Resignations	02/04
Camurus Annual Report for 2023	28/03
Camurus' New Drug Application for Acromegaly Treatment Accepted by US FDA	05/03
Camurus announces FDA acceptance of NDA submission for Oclaiz™ for treatment of acromegaly	05/03
Camurus AB Announces FDA Acceptance of NDA Submission for Oclaiz? for Treatment of Acromegaly	05/03
AVIS D'ANALYSTES DU JOUR : Sanofi, Stellantis, Orange, STMicroelectronics, OVH, UCB, Valeo...	04/03
Camurus AB Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
Nordic Shares Rose Thursday; Tomra Systems Climbed Highest	15/02
Camurus' Full Year Report 2023	15/02
Camurus AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/02
Camurus AB Provides Earnings Guidance for the Full Year 2024	15/02
Camurus appoints Behshad Sheldon as President of Camurus Inc.	13/02
Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024	13/02
Completed enrollment in the POSITANO study of CAM2029 in patients with polycystic liver disease	08/02
Camurus AB Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease	08/02
Nordic Stocks Rose Thursday; Kinnevik Series B Topped Leaders	18/01
Camurus has carried out a directed share issue of 2,000,000 shares at a subscription price of SEK 545 per share, raising gross proceeds of SEK 1,090 million	18/01
Camurus intends to carry out a directed share issue of approximately 2 million shares and provides preliminary financial information for FY 2023	17/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Camurus AB

Acciones

CAMX

SE0007692850

Otros idiomas

Filtros